Motilal Oswal: Cipla’s Revlimid Litigation Settlement Improves Business Visibility
BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Motilal Oswal Report
Cipla Ltd. and Celgene (innovator) have reached an agreement to settle the litigation pertaining to g-Revlimid in the U.S.
As per the settlement, the company can begin selling g-Revlimid in the U.S. sometime after March 2022.
Considering other settlements, limited build-up of sales over FY23-26E, and unlimited quantities of g-Revlimid by Cipla post January-26E, there could be a potential net present value addition of Rs 40 per share from this opportunity.
We await clarity on further details of the agreement.
Click on the attachment to read the full report:
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the brokerage and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.